1.09

11.75% 0.1146

After Hours: 1.13 0.04 +3.67%

Cognition Therapeutics Inc (CGTX)

Overview News Price History Financials Discussions Forecast

Cognition Therapeutics Inc stock is traded at $1.09, with a volume of 1.04M. It is up +11.75% in the last 24 hours and up +3.81% over the past month. Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Previous Close:

$0.9754

Open:

$0.99

24h Volume:

1.04M

Relative Volume:

1.01

Market Cap:

$97.40M

Revenue:

Net Income/Loss:

$-23.49M

P/E Ratio:

-3.1714

EPS:

-0.3437

Net Cash Flow:

$-24.59M

1W Performance:

+23.84%

1M Performance:

+3.81%

6M Performance:

-40.44%

1Y Performance:

+184.37%

1-Day Range:

$0.98

$1.105

1-Week Range:

$0.8532

$1.105

52-Week Range:

$0.2223

$3.83

Cognition Therapeutics Inc Stock (CGTX) Company Profile

Name

Cognition Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

412-481-2210

Address

2500 WESTCHESTER AVE, PURCHASE

Employee

Twitter

Next Earnings Date

2026-03-26

Latest SEC Filings

CGTX's Discussions on Twitter

Compare CGTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGTX Cognition Therapeutics Inc	1.09	87.16M	0	-23.49M	-24.59M	-0.3437
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Upgrade	B. Riley Securities	Neutral → Buy
Jul-30-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-03-21	Initiated	B. Riley Securities	Buy
Nov-03-21	Initiated	Oppenheimer	Outperform

Cognition Therapeutics Inc Stock (CGTX) Latest News

Apr 13, 2026

CGTX: Phase III trials for zervimesine in DLB psychosis and Alzheimer's are advancing with strong safety and efficacy data - TradingView — Track All Markets

Apr 13, 2026

Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans - Yahoo Finance

Apr 13, 2026

Update Report: Can Cognition Therapeutics Inc disrupt its industryQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn

Apr 13, 2026

Insider Trends: Whats the fair value of Cognition Therapeutics Inc stockSell Signal & Real-Time Market Sentiment Reports - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Insider Sell: Can Cognition Therapeutics Inc disrupt its industryPortfolio Gains Summary & Daily Stock Momentum Reports - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Big Picture: Whats the fair value of Cognition Therapeutics Inc stockQuarterly Trade Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Lewy Body Dementia Market: Accelerating Growth and Pipeline Impact by 2034– DelveInsight | Cognition Therapeutics, KeifeRx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics - Barchart

Apr 09, 2026

Lewy Body Dementia Market: Accelerating Growth and Pipeline - openPR.com

Apr 09, 2026

Apr 07, 2026

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference - Bitget

Apr 07, 2026

Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at 25th Annual Needham Virtual Healthcare Conference - Quiver Quantitative

Apr 07, 2026

CEO to give Alzheimer's, Lewy body drug update on April 13 - Stock Titan

Apr 07, 2026

Apr 06, 2026

Fed Meeting: What is the PEG ratio of Cognition Therapeutics Inc2026 Outlook & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn

Apr 06, 2026

Apr 03, 2026

Cognition Therapeutics plans late-stage trial for dementia drug By Investing.com - Investing.com Australia

Apr 01, 2026

Mar 31, 2026

Cognition Therapeutics plans late-stage trial for dementia drug - Investing.com

Mar 31, 2026

Mar 30, 2026

Cognition Plunges 21.8% on Intraday Carnage — What’s Triggering This Sharp Drop? - Bitget

Mar 30, 2026

Q1 Earnings Forecast for CGTX Issued By HC Wainwright - MarketBeat

Mar 30, 2026

Mar 28, 2026

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation - Sahm

Mar 28, 2026

Mar 27, 2026

Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets

Mar 27, 2026

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 27, 2026

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Mar 27, 2026

Cognition Therapeutics (NASDAQ:CGTX) Receives Buy Rating from Chardan Capital - MarketBeat

Mar 27, 2026

Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial By Investing.com - Investing.com South Africa

Mar 27, 2026

Mar 26, 2026

Cognition Therapeutics Reports 2025 Financial Results and Advances Zervimesine for DLB Psychosis and Alzheimer’s Clinical Trials - Minichart

Mar 26, 2026